Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Earnings Highlights: Takeda, Astellas And Eisai

This article was originally published in PharmAsia News

Executive Summary

Takeda preps for cost-cutting program; Astellas clears path for Xtandi; and Eisai leans on Belviq in the U.S. with aggressive coverage program.

You may also be interested in...



Takeda Has Another Shot Remaining With Orteronel In Prostate Cancer

Phase III ELM-PC 5 study of orteronel in post-chemo metastatic castration-resistant prostate cancer is unblinded after drug fails to improve overall survival. But the company is continuing a Phase III trial in an earlier line of therapy.

European Notebook: Renewed Calls For German Pricing Law Changes, Spain Gauges The Value Of Innovation

German health insurers run a cash surplus in the first quarter; Celesio CEO dismissed; Bayer celebrates 150 years; Spain wants to evaluate value for drug pricing; France's drug spend declines in 2012, and more.

Obesity Drugs Could Get Lift From Part D Legislation, AMA Policy

Two events lead the way to greater coverage and reimbursement for obesity drugs: a bipartisan, bicameral bill that would remove Medicare Part D’s ban on covering obesity drugs and AMA’s recognition of obesity as a disease.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1126271

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel